Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$151.33
+1.2%
$150.86
$127.59
$187.35
$41.21B0.222.91 million shs2.08 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$72.86
+0.4%
$64.83
$54.11
$89.98
$28.01B1.456.82 million shs4.82 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$80.13
+0.2%
$86.27
$51.79
$101.40
$10.86B0.952.04 million shs1.60 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$562.16
-0.5%
$563.32
$506.91
$769.98
$44.55B1.55635,392 shs459,089 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+2.71%+0.74%+3.69%-10.66%-12.52%
DexCom, Inc. stock logo
DXCM
DexCom
-0.25%+0.35%+22.04%+6.59%-15.21%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+2.71%-3.17%-11.05%-8.14%+34.07%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.72%-0.58%+0.31%-7.18%+7.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$151.33
+1.2%
$150.86
$127.59
$187.35
$41.21B0.222.91 million shs2.08 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$72.86
+0.4%
$64.83
$54.11
$89.98
$28.01B1.456.82 million shs4.82 million shs
Globus Medical, Inc. stock logo
GMED
Globus Medical
$80.13
+0.2%
$86.27
$51.79
$101.40
$10.86B0.952.04 million shs1.60 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$562.16
-0.5%
$563.32
$506.91
$769.98
$44.55B1.55635,392 shs459,089 shs
7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
+2.71%+0.74%+3.69%-10.66%-12.52%
DexCom, Inc. stock logo
DXCM
DexCom
-0.25%+0.35%+22.04%+6.59%-15.21%
Globus Medical, Inc. stock logo
GMED
Globus Medical
+2.71%-3.17%-11.05%-8.14%+34.07%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
+0.72%-0.58%+0.31%-7.18%+7.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
2.38
Hold$183.6421.35% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.92
Moderate Buy$82.6313.40% Upside
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.87
Moderate Buy$106.3632.74% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.64
Moderate Buy$751.0033.59% Upside

Current Analyst Ratings Breakdown

Latest GMED, IDXX, BDX, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetBuy$85.00 ➝ $90.00
6/1/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingHold (C-)
5/28/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingBuy$79.00 ➝ $84.00
5/27/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Lower Price TargetNeutral$156.00 ➝ $150.00
5/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
Set Price TargetBuy$100.00 ➝ $82.00
5/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
Reiterated RatingUnderweight$67.00 ➝ $64.00
5/18/2026
DexCom, Inc. stock logo
DXCM
DexCom
Lower Price TargetBuy$100.00 ➝ $80.00
5/15/2026
DexCom, Inc. stock logo
DXCM
DexCom
UpgradeStrong-Buy
5/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Initiated CoverageBuy$77.00
5/11/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
DowngradeHold (C-)Sell (D+)
5/11/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
DowngradeHold (C+)Hold (C)
(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$21.84B1.91$23.35 per share6.48$88.58 per share1.71
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.03$2.78 per share26.22$7.04 per share10.35
Globus Medical, Inc. stock logo
GMED
Globus Medical
$2.94B3.70$6.29 per share12.73$33.86 per share2.37
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.30B10.30$15.02 per share37.43$20.10 per share27.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.68B$3.9538.3111.0010.595.33%15.37%7.11%8/6/2026 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.3431.1424.211.1419.31%33.33%13.19%7/29/2026 (Estimated)
Globus Medical, Inc. stock logo
GMED
Globus Medical
$537.87M$4.3018.6315.841.6518.92%13.46%11.65%8/6/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$13.5841.4034.013.0924.63%70.87%32.56%8/3/2026 (Estimated)

Latest GMED, IDXX, BDX, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q2 2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$2.77$2.90+$0.13-$1.11$4.67 billion$4.71 billion
5/7/2026Q1 2026
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.92$1.12+$0.20$0.90$740.35 million$759.85 million
5/5/2026Q1 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.41$3.47+$0.06$3.47$1.12 billion$1.14 billion
4/30/2026Q1 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.202.78%+5.65%106.33%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest GMED, IDXX, BDX, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/28/2026
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.052.81%6/9/20266/9/20266/30/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.62
0.94
0.55
DexCom, Inc. stock logo
DXCM
DexCom
0.42
1.95
1.64
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/A
4.56
2.95
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.12
0.82

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.40%
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Globus Medical, Inc. stock logo
GMED
Globus Medical
18.38%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
72,000275.54 million274.44 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000385.87 million384.79 millionOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
6,000135.74 million110.80 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.88 million78.26 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$151.33 +1.77 (+1.19%)
Closing price 03:59 PM Eastern
Extended Trading
$150.00 -1.33 (-0.88%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$72.86 +0.27 (+0.37%)
Closing price 04:00 PM Eastern
Extended Trading
$72.21 -0.65 (-0.89%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Globus Medical stock logo

Globus Medical NYSE:GMED

$80.13 +0.13 (+0.16%)
Closing price 03:59 PM Eastern
Extended Trading
$79.99 -0.14 (-0.17%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$562.16 -2.58 (-0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$558.14 -4.01 (-0.71%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.